{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:01:07Z","timestamp":1791932467574,"version":"4.3.4"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbrc.2025.152197","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:03:06Z","timestamp":1750100586000},"page":"152197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A novel Nav1.7, Nav1.8, and Nav1.9 blocker, ANP-230, has broad analgesic efficacy in preclinical pain models with favorable safety margins"],"prefix":"10.1016","volume":"777","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3418-5691","authenticated-orcid":false,"given":"Tatsuya","family":"Kamei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-558X","authenticated-orcid":false,"given":"Yoshihiro","family":"Oyamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152197_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbrc.2025.152197_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abj9837","article-title":"Developing nociceptor-selective treatments for acute and chronic pain","volume":"13","author":"Jayakar","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2025.152197_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14656566.2022.2060741","article-title":"The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain","volume":"23","author":"D'Souza","year":"2022","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.152197_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41583-021-00444-w","article-title":"The physiological function of different voltage-gated sodium channels in pain","volume":"22","author":"Goodwin","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbrc.2025.152197_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbrc.2025.152197_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-020-00415-2","article-title":"Status of peripheral sodium channel blockers for non-addictive pain treatment","volume":"16","author":"Alsaloum","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbrc.2025.152197_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1749-6632.2009.05110.x","article-title":"Familial pain syndromes from mutations of the Nav1.7 sodium channel","volume":"1184","author":"Fischer","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbrc.2025.152197_bib8","doi-asserted-by":"crossref","first-page":"19444","DOI":"10.1073\/pnas.1216080109","article-title":"Gain-of-function Nav1.8 mutations in painful neuropathy","volume":"109","author":"Faber","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.bbrc.2025.152197_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/brain\/awu079","article-title":"Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy","volume":"137","author":"Huang","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.bbrc.2025.152197_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0208516","article-title":"Familial episodic limb pain in kindreds with novel Nav1.9 mutations","volume":"13","author":"Kabata","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.152197_bib11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/ng.2767","article-title":"A de novo gain-of-function mutation in SCN11A causes loss of pain perception","volume":"45","author":"Leipold","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2025.152197_bib12","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1021\/acs.jmedchem.8b01906","article-title":"Challenges and opportunities for therapeutics targeting the voltage-gated sodium channel isoform NaV1.7","volume":"62","author":"Mulcahy","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152197_bib13","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1111\/bph.15327","article-title":"Fifteen years of NaV1.7 channels as an analgesic target: why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?","volume":"179","author":"Eagles","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1039\/D2MD00081D","article-title":"Inhibition of NaV1.7: the possibility of ideal analgesics","volume":"13","author":"Kitano","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152197_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of Na V 1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152197_bib16","doi-asserted-by":"crossref","DOI":"10.1124\/molpharm.124.000944","article-title":"strong>State-dependent inhibition of Nav1.8 channels by VX-150 and VX-548<\/strong&gt","author":"Vaelli","year":"2024","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib17","year":"2025"},{"key":"10.1016\/j.bbrc.2025.152197_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/molpharm.123.000789","article-title":"Pharmacologic characterization of LTGO-33, a selective small molecule inhibitor of the voltage-gated sodium channel NaV1.8 with a unique mechanism of ActionS","volume":"105","author":"Gilchrist","year":"2024","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib19","article-title":"US national library of medicine","year":"2024","journal-title":"ClinicalTrials.gov"},{"key":"10.1016\/j.bbrc.2025.152197_bib20","article-title":"Biophysical and pharmacological characterization of Nav1.9 voltage dependent sodium channels stably expressed in HEK-293 cells","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.152197_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00852","article-title":"Electrophysiological and pharmacological analyses of Nav1.9 voltage-gated sodium channel by establishing a heterologous expression system","volume":"8","author":"Zhou","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0021-9258(17)49917-0","article-title":"A 49-residue sequence motif in the C terminus of Nav1.9 regulates trafficking of the channel to the plasma membrane","volume":"295","author":"Sizova","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152197_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/brain\/awy329","article-title":"Lacosamide in patients with Na v 1.7 mutations-related small fibre neuropathy: a randomized controlled trial","volume":"142","author":"De Greef","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.bbrc.2025.152197_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/j.pain.0000000000002693","article-title":"Ambroxol for neuropathic pain: hiding in plain sight?","volume":"164","author":"Russo","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jpain.2020.11.002","article-title":"Analgesic effects of topical amitriptyline in patients with chemotherapy-induced peripheral neuropathy: mechanistic insights from studies in mice","volume":"22","author":"Genevois","year":"2021","journal-title":"J. Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116743","article-title":"Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7\/Nav1.8 blockers for the treatment of pain","volume":"63","author":"Patel","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152197_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109057","article-title":"The small molecule compound C65780 alleviates pain by stabilizing voltage-gated sodium channels in the inactivated and slowly-recovering state","volume":"212","author":"Kong","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbrc.2025.152197_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150126","article-title":"Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230","volume":"721","author":"Kamei","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.152197_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15423","article-title":"Reduced pain sensitivity of episodic pain syndrome model mice carrying a Nav1.9 mutation by ANP-230, a novel sodium channel blocker","volume":"9","author":"Okuda","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2025.152197_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pme.12063","article-title":"Small molecule angiotensin II type 2 receptor (AT 2 R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats","volume":"14","author":"Smith","year":"2013","journal-title":"Pain Med."},{"key":"10.1016\/j.bbrc.2025.152197_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0304-3959(92)90041-9","article-title":"An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat","volume":"50","author":"Ho Kim","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.bbrc.2025.152197_bib34","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1476-5381.2010.01192.x","article-title":"Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain","volume":"163","author":"Guindon","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0304-3959(99)00024-X","article-title":"Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat","volume":"81","author":"Fox","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neuropharm.2009.06.037","article-title":"Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats","volume":"57","author":"Yamamoto","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbrc.2025.152197_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-Based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib38","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.bbrc.2025.152197_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neulet.2013.08.004","article-title":"Voltage gated sodium and calcium channel blockers for the treatment of chronic inflammatory pain","volume":"557","author":"Rahman","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbrc.2025.152197_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00263","article-title":"Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes","volume":"6","author":"Laedermann","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1744806919858801","article-title":"Nav1.7 and Nav1.8: role in the pathophysiology of pain","volume":"15","author":"Hameed","year":"2019","journal-title":"Mol. Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib42","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrn3977","article-title":"NaV1.9: a sodium channel linked to human pain","volume":"16","author":"Dib-Hajj","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbrc.2025.152197_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejpain.2009.02.003","article-title":"Antinociceptive effect of the cannabinoid agonist, WIN 55,212\u20102, in the orofacial and temporomandibular formalin tests","volume":"14","author":"Burgos","year":"2010","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neures.2009.10.009","article-title":"Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats","volume":"66","author":"Bardin","year":"2010","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.bbrc.2025.152197_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbb.2008.06.008","article-title":"Additive interaction between peripheral and central mechanisms involved in the antinociceptive effect of diclofenac in the formalin test in rats","volume":"91","author":"Ortiz","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbrc.2025.152197_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","article-title":"The formalin test: an evaluation of the method","volume":"51","author":"Tj\u00f8lsen","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib48","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1248\/bpb.34.1170","article-title":"Prostaglandin E2 and pain - an update","volume":"34","author":"Kawabata","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbrc.2025.152197_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13543784.2017.1260544","article-title":"Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain","volume":"26","author":"Gr\u00f6sch","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2025.152197_bib50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bcp.2008.11.015","article-title":"The peripheral pro-nociceptive state induced by repetitive inflammatory stimuli involves continuous activation of protein kinase A and protein kinase C epsilon and its NaV1.8 sodium channel functional regulation in the primary sensory neuron","volume":"77","author":"Villarreal","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1476-5381.2012.02174.x","article-title":"scp>AKAP<\/scp> \u2010dependent sensitization of <scp>Ca<\/scp> v 3.2 channels via the <scp>EP<\/scp> 4 receptor\/c <scp>AMP<\/scp> pathway mediates <scp>PGE<\/scp> 2 \u2010induced mechanical hyperalgesia","volume":"168","author":"Sekiguchi","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib52","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/bph.16398","article-title":"ST-2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non-human Primates","author":"Mulcahy","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.neuroscience.2006.08.005","article-title":"Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity","volume":"143","author":"Joshi","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbrc.2025.152197_bib54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14728222.2012.680955","article-title":"Targeting pain mediators induced by injured nerve-derived COX2 and PGE2 to treat neuropathic pain","volume":"16","author":"Ma","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2025.152197_bib55","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-3565(24)38937-2","article-title":"Analgesic synergy between topical lidocaine and topical opioids","volume":"295","author":"Kolesnikov","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.bbrc.2025.152197_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1526-4637.2009.00768.x","article-title":"Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain","volume":"11","author":"Kolosov","year":"2010","journal-title":"Pain Med."},{"key":"10.1016\/j.bbrc.2025.152197_bib57","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/j.pain.0000000000001567","article-title":"Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain","volume":"160","author":"Mueller","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib58","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2165\/00003495-200464240-00006","article-title":"Pregabalin: in the treatment of painful diabetic peripheral neuropathy","volume":"64","author":"Frampton","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.152197_bib59","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuroscience.2008.02.031","article-title":"Pharmacological characterization and gene expression profiling of an L5\/L6 spinal nerve ligation model for neuropathic pain in mice","volume":"153","author":"Kiso","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbrc.2025.152197_bib60","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuropharm.2008.01.001","article-title":"Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans","volume":"54","author":"Whiteside","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbrc.2025.152197_bib61","author":"Honor\u00e9"},{"key":"10.1016\/j.bbrc.2025.152197_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9967","article-title":"Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7","volume":"6","author":"Minett","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2025.152197_bib63","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jpain.2022.12.012","article-title":"NaV1.7 channel blocker [ala5, Phe6, Leu26, Arg28]GpTx-1 attenuates CFA-Induced inflammatory hypersensitivity in rats via endogenous enkephalin mechanism","volume":"24","author":"Xu","year":"2023","journal-title":"J. Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib64","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.neuron.2023.05.024","article-title":"Nav1.7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids","volume":"111","author":"Deng","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.bbrc.2025.152197_bib65","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.neuron.2023.08.011","article-title":"NaV1.7: a central role in pain","volume":"111","author":"Waxman","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.bbrc.2025.152197_bib66","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/j.pain.0000000000002112","article-title":"Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain","volume":"162","author":"Beckley","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib67","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/j.pain.0000000000003026","article-title":"How do opioids control pain circuits in the brainstem during opioid-induced disorders and in chronic pain? Implications for the treatment of chronic pain","volume":"165","author":"Costa","year":"2024","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnsys.2022.1059089","article-title":"Mu-opioid receptor and receptor tyrosine kinase crosstalk: implications in mechanisms of opioid tolerance, reduced analgesia to neuropathic pain, dependence, and reward","volume":"16","author":"Gamble","year":"2022","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.bbrc.2025.152197_bib69","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1021\/acs.jmedchem.6b00063","article-title":"Substituted indazoles as Nav1.7 blockers for the treatment of pain","volume":"59","author":"Frost","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152197_bib70","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.celrep.2018.08.063","article-title":"Selective NaV1.7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain","volume":"24","author":"Bankar","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2025.152197_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pain.2005.04.017","article-title":"Neuropathic pain: early spontaneous afferent activity is the trigger","volume":"116","author":"Xie","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib72","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pain.2010.06.019","article-title":"The evidence for pharmacological treatment of neuropathic pain","volume":"150","author":"Finnerup","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13543784.2020.1728254","article-title":"Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers","volume":"29","author":"Kushnarev","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2025.152197_bib74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejphar.2014.04.003","article-title":"Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine","volume":"735","author":"Le Cudennec","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph17070838","article-title":"Sex-gender differences are completely neglected in treatments for neuropathic pain","volume":"17","author":"Salis","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.152197_bib76","first-page":"1","article-title":"Molecular mechanisms of sex-related differences in arthritis and associated pain","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152197_bib77","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1523\/JNEUROSCI.1499-20.2020","article-title":"Neuroendocrine mechanisms governing sex differences in hyperalgesic priming involve prolactin receptor sensory neuron signaling","volume":"40","author":"Paige","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2025.152197_bib78","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/j.pain.0000000000001399","article-title":"Targeting the Nav1.8 ion channel engenders sex-specific responses in lysophosphatidic acid\u2013induced joint neuropathy","volume":"160","author":"O'Brien","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.bbrc.2025.152197_bib79","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1111\/bph.14461","article-title":"GpTx-1 and [ala5, Phe6, Leu26, Arg28]GpTx-1, two peptide NaV1.7 inhibitors: analgesic and tolerance properties at the spinal level","volume":"175","author":"Chen","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152197_bib80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pbb.2015.11.008","article-title":"Spontaneous and evoked pain-associated behaviors in a rat model of neuropathic pain respond differently to drugs with different mechanisms of action","volume":"141","author":"Murai","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbrc.2025.152197_bib81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/JPR.S124526","article-title":"Differential drug effects on spontaneous and evoked pain behavior in a model of trigeminal neuropathic pain","volume":"10","author":"Deseure","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.bbrc.2025.152197_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fpain.2021.750583","article-title":"Peripheral voltage-gated cation channels in neuropathic pain and their potential as therapeutic targets","volume":"2","author":"Alles","year":"2021","journal-title":"Front. Pain Res"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2500912X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2500912X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:44:07Z","timestamp":1774860247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2500912X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":82,"alternative-id":["S0006291X2500912X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152197","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel Nav1.7, Nav1.8, and Nav1.9 blocker, ANP-230, has broad analgesic efficacy in preclinical pain models with favorable safety margins","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152197"}}